Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. The AAFP recognizes the benefits of intervention and treatment for the recreational use of marijuana, in lieu of incarceration, for all individuals, including youth.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Canna Law Blog

OCTOBER 1, 2020

According to the CSA (and subsequent regulations ), Schedule I substances have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. In 2006, the U.S. DEA Interim Guidelines. The Schedule I listing was significant.

History 98

History Law DEA Safety 98

Cannabis Law Report

JULY 12, 2019

Ultimately, the cannabinoid system works by way of multiple molecules affecting multiple receptors at once – the entourage effect, and thus such singular approaches to treatment by way of the cannabinoid system are not effective. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Fabricio A.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Weedistry

MARCH 7, 2019

The results were published in 2006 in the British Journal of Pharmacology : THC treatment was associated with significantly reduced tumor cell proliferation in every test subject. Italian investigators described CBD as “the most efficacious inducer of apoptosis” in prostate cancer.

THC 40

THC CBD Clinical Trials Research and Development 40